DanDrit Biotech USA, a biotechnology company developing a vaccine for the treatment of colorectal cancer, has signed a final collaboration agreement with GISCAD Foundation, an Italian group focused on digestive tract cancer studies.

The collaboration relates to VIVA, a phase III adjuvant trial of DanDrit vaccine, in patients with no evidence of disease stage IV colorectal cancer. The primary aim of the VIVA clinical trial is to evaluate the ability of MelCancerVac (MCV) to prevent a relapse in stage IV CRC patients rendered disease free after completion of standard treatment according to local practices. Professor Alberto Sobrero will be the Principal Investigator of this randomized multicenter study.

"The VIVA phase III randomized multicenter clinical trial design," said Dr. Paolo Bruzzi, UOC di Epidemiologia Clinica, "is designed to ensure that the results will be representative of the potential benefits of MCV as a new tool in the treatment of advanced colorectal cancer."